Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial
The prospective, randomized phase III trial GMMG-HD2 aimed at demonstrating non-inferiority of single (Arm A) versus tandem (Arm B) high-dose melphalan followed by autologous transplantation (HDM/ASCT) with regard to 2-year event-free survival (EFS) in newly-diagnosed multiple myeloma (MM) and inclu...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
17 March 2016
|
| In: |
British journal of haematology
Year: 2016, Volume: 173, Issue: 5, Pages: 731-741 |
| ISSN: | 1365-2141 |
| DOI: | 10.1111/bjh.13994 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1111/bjh.13994 Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13994 
|
| Author Notes: | Elias K. Mai, Axel Benner, Uta Bertsch, Peter Brossart, Annette Hänel, Volker Kunzmann, Ralph Naumann, Kai Neben, Gerlinde Egerer, Anthony D. Ho, Jens Hillengass, Marc S. Raab, Andreas Neubauer, Astrid Peyn, Yon-Dschun Ko, Norma Peter, Christof Scheid and Hartmut Goldschmidt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1671369564 | ||
| 003 | DE-627 | ||
| 005 | 20220816205716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190814s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.13994 |2 doi | |
| 035 | |a (DE-627)1671369564 | ||
| 035 | |a (DE-599)KXP1671369564 | ||
| 035 | |a (OCoLC)1341235793 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mai, Elias K. |d 1985- |e VerfasserIn |0 (DE-588)1049182545 |0 (DE-627)781300274 |0 (DE-576)403130999 |4 aut | |
| 245 | 1 | 0 | |a Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma |b long-term results from the phase III GMMG-HD2 trial |c Elias K. Mai, Axel Benner, Uta Bertsch, Peter Brossart, Annette Hänel, Volker Kunzmann, Ralph Naumann, Kai Neben, Gerlinde Egerer, Anthony D. Ho, Jens Hillengass, Marc S. Raab, Andreas Neubauer, Astrid Peyn, Yon-Dschun Ko, Norma Peter, Christof Scheid and Hartmut Goldschmidt |
| 264 | 1 | |c 17 March 2016 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.08.2019 | ||
| 520 | |a The prospective, randomized phase III trial GMMG-HD2 aimed at demonstrating non-inferiority of single (Arm A) versus tandem (Arm B) high-dose melphalan followed by autologous transplantation (HDM/ASCT) with regard to 2-year event-free survival (EFS) in newly-diagnosed multiple myeloma (MM) and included 358 evaluable patients [Intention-to-treat population, (ITT), single/tandem HDM/ASCT: n = 177/181]. After a median follow-up of more than 11 years, non-inferiority of single versus tandem HDM/ASCT was demonstrated using the planned non-inferiority threshold of 15% of the 2-year EFS rate. Neither EFS (P = 0·53) nor overall survival (OS) (P = 0·33) differences were observed in the ITT population. In the tandem arm, 26% (n = 47/181) of patients refused a second HDM/ASCT due to non-medical reasons. A per-protocol (PP) analysis, including patients who received the intervention (single/tandem HDM/ASCT: n = 156/93) and patients who did not receive a second HDM/ASCT due to medical reasons (12%, n = 22/181), did not yield differences in EFS (P = 0·61) or OS (P = 0·16). In the ITT and PP set of the tandem arm, the rates of complete responses increased from first to second HDM/ASCT (both P = 0·04). Ten-year OS for the entire ITT was 34% (95% confidence interval: 29-40%). OS after first relapse was significantly shortened in the tandem arm (P = 0·04). In this study single HDM/ASCT was non-inferior to tandem HDM/ASCT in MM. | ||
| 650 | 4 | |a melphalan | |
| 650 | 4 | |a myeloma | |
| 650 | 4 | |a single transplantation | |
| 650 | 4 | |a stem cell transplantation | |
| 650 | 4 | |a tandem transplantation | |
| 700 | 1 | |a Bertsch, Uta |e VerfasserIn |0 (DE-588)1026849861 |0 (DE-627)727494163 |0 (DE-576)372176224 |4 aut | |
| 700 | 1 | |a Egerer, Gerlinde |e VerfasserIn |0 (DE-588)105502168X |0 (DE-627)792516745 |0 (DE-576)167430882 |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Hillengaß, Jens |d 1974- |e VerfasserIn |0 (DE-588)124918549 |0 (DE-627)368073823 |0 (DE-576)294568298 |4 aut | |
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d Oxford [u.a.] : Wiley-Blackwell, 1955 |g 173(2016), 5, Seite 731-741 |h Online-Ressource |w (DE-627)269758941 |w (DE-600)1475751-5 |w (DE-576)09113997X |x 1365-2141 |7 nnas |a Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma long-term results from the phase III GMMG-HD2 trial |
| 773 | 1 | 8 | |g volume:173 |g year:2016 |g number:5 |g pages:731-741 |g extent:11 |a Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma long-term results from the phase III GMMG-HD2 trial |
| 856 | 4 | 0 | |u https://doi.org/10.1111/bjh.13994 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13994 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190814 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 18 |y j | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |d 910100 |e 910000PR124052460 |e 910100PR124052460 |k 0/910000/ |k 1/910000/910100/ |p 12 | ||
| 998 | |g 124918549 |a Hillengaß, Jens |m 124918549:Hillengaß, Jens |d 910000 |d 910100 |e 910000PH124918549 |e 910100PH124918549 |k 0/910000/ |k 1/910000/910100/ |p 11 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 10 | ||
| 998 | |g 105502168X |a Egerer, Gerlinde |m 105502168X:Egerer, Gerlinde |d 910000 |d 910100 |e 910000PE105502168X |e 910100PE105502168X |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 998 | |g 1026849861 |a Bertsch, Uta |m 1026849861:Bertsch, Uta |d 910000 |d 910100 |e 910000PB1026849861 |e 910100PB1026849861 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 1049182545 |a Mai, Elias K. |m 1049182545:Mai, Elias K. |d 910000 |d 910100 |e 910000PM1049182545 |e 910100PM1049182545 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1671369564 |e 3506938142 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1111/bjh.13994"],"eki":["1671369564"]},"name":{"displayForm":["Elias K. Mai, Axel Benner, Uta Bertsch, Peter Brossart, Annette Hänel, Volker Kunzmann, Ralph Naumann, Kai Neben, Gerlinde Egerer, Anthony D. Ho, Jens Hillengass, Marc S. Raab, Andreas Neubauer, Astrid Peyn, Yon-Dschun Ko, Norma Peter, Christof Scheid and Hartmut Goldschmidt"]},"physDesc":[{"extent":"11 S."}],"recId":"1671369564","relHost":[{"corporate":[{"display":"British Society for Haematology","role":"isb"},{"role":"isb","display":"European Hematology Association"}],"language":["eng"],"part":{"volume":"173","extent":"11","year":"2016","pages":"731-741","text":"173(2016), 5, Seite 731-741","issue":"5"},"titleAlt":[{"title":"the official journal of the British Society of Haematology"},{"title":"BJH ; the official journal of the British Society for Haematology"}],"title":[{"title":"British journal of haematology","title_sort":"British journal of haematology","subtitle":"BJHaem : an official journal of the British Society for Haematology"}],"origin":[{"publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell","dateIssuedKey":"1955","dateIssuedDisp":"1955-","publisherPlace":"Oxford [u.a.] ; Oxford ; Oxford [u.a.]"}],"note":["Gesehen am 08.05.08"],"pubHistory":["1.1955 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma long-term results from the phase III GMMG-HD2 trialBritish journal of haematology","recId":"269758941","physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["ed. R. B. Thompson [u.a.]"]},"id":{"eki":["269758941"],"zdb":["1475751-5"],"issn":["1365-2141"],"doi":["10.1111/(ISSN)1365-2141"]}}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"17 March 2016"}],"note":["Gesehen am 14.08.2019"],"title":[{"title_sort":"Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma","subtitle":"long-term results from the phase III GMMG-HD2 trial","title":"Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma"}],"language":["eng"],"person":[{"display":"Mai, Elias K.","family":"Mai","role":"aut","given":"Elias K."},{"display":"Bertsch, Uta","family":"Bertsch","role":"aut","given":"Uta"},{"role":"aut","given":"Gerlinde","family":"Egerer","display":"Egerer, Gerlinde"},{"given":"Anthony Dick","role":"aut","display":"Ho, Anthony Dick","family":"Ho"},{"display":"Hillengaß, Jens","family":"Hillengaß","given":"Jens","role":"aut"},{"family":"Raab","display":"Raab, Marc-Steffen","role":"aut","given":"Marc-Steffen"},{"given":"Hartmut","role":"aut","display":"Goldschmidt, Hartmut","family":"Goldschmidt"}]} | ||
| SRT | |a MAIELIASKBSINGLEVERS1720 | ||